<!DOCTYPE html>
<html lang="en" dir="auto">

<head>
<head>
    <title>infectious diseases</title>
    <meta charset="utf-8">
    <meta name="description"
        content="Website meta description for google search results go here" />
    <meta name="dc.relation" content="https://trxiv.yorks0n.com" />
    <meta name="viewport" content="width=device-width, initial-scale=1, shrink-to-fit=no">
    <meta name="theme-color" content="#1A94D2" />

    

    
    
    
    <link rel="stylesheet" href="/css/main.min.css" media="screen">

</head>


<meta charset="utf-8">
<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta name="viewport" content="width=device-width, initial-scale=1, shrink-to-fit=no">
<meta name="robots" content="index, follow">
<title>infectious diseases | TRxiv2</title>
<meta name="keywords" content="">
<meta name="description" content="Safety and Immunogenicity of XBB.1.5-Containing mRNA Vaccines
Authors: Chalkias, S.; McGhee, N.; Whatley, J. L.; Essink, B.; Brosz, A.; Tomassini, J. E.; Girard, B.; Wu, K.; Edwards, D. K.; Nasir, A.; Lee, D.; Avena, L. E.; Feng, J.; Deng, W.; Montefiori, D. C.; Baden, L. R.; Miller, J. M.; Das, R.
Score: 2048.9, Published: 2023-09-07 DOI: 10.1101/2023.08.22.23293434
Background: Subvariants of the severe acute respiratory syndrome coronavirus (SARS-CoV-2) omicron XBB-lineage have the potential to escape immunity provided by prior infection or vaccination.">
<meta name="author" content="">
<link rel="canonical" href="https://trxiv.yorks0n.com/posts/infectious-diseases/">
<link crossorigin="anonymous" href="/assets/css/stylesheet.904bd1e751cdd2a584fa6bed3fa1166dfd8ec9949ebfd0c4d69c5add5e17c23d.css" integrity="sha256-kEvR51HN0qWE&#43;mvtP6EWbf2OyZSev9DE1pxa3V4Xwj0=" rel="preload stylesheet" as="style">
<script defer crossorigin="anonymous" src="/assets/js/highlight.f413e19d0714851f6474e7ee9632408e58ac146fbdbe62747134bea2fa3415e0.js" integrity="sha256-9BPhnQcUhR9kdOfuljJAjlisFG&#43;9vmJ0cTS&#43;ovo0FeA="
    onload="hljs.initHighlightingOnLoad();"></script>
<link rel="icon" href="https://trxiv.yorks0n.com/favicon.ico">
<link rel="icon" type="image/png" sizes="16x16" href="https://trxiv.yorks0n.com/favicon-16x16.png">
<link rel="icon" type="image/png" sizes="32x32" href="https://trxiv.yorks0n.com/favicon-32x32.png">
<link rel="apple-touch-icon" href="https://trxiv.yorks0n.com/apple-touch-icon.png">
<link rel="mask-icon" href="https://trxiv.yorks0n.com/safari-pinned-tab.svg">
<meta name="theme-color" content="#2e2e33">
<meta name="msapplication-TileColor" content="#2e2e33">
<noscript>
    <style>
        #theme-toggle,
        .top-link {
            display: none;
        }

    </style>
    <style>
        @media (prefers-color-scheme: dark) {
            :root {
                --theme: rgb(29, 30, 32);
                --entry: rgb(46, 46, 51);
                --primary: rgb(218, 218, 219);
                --secondary: rgb(155, 156, 157);
                --tertiary: rgb(65, 66, 68);
                --content: rgb(196, 196, 197);
                --hljs-bg: rgb(46, 46, 51);
                --code-bg: rgb(55, 56, 62);
                --border: rgb(51, 51, 51);
            }

            .list {
                background: var(--theme);
            }

            .list:not(.dark)::-webkit-scrollbar-track {
                background: 0 0;
            }

            .list:not(.dark)::-webkit-scrollbar-thumb {
                border-color: var(--theme);
            }
        }

    </style>
</noscript><meta property="og:title" content="infectious diseases" />
<meta property="og:description" content="Safety and Immunogenicity of XBB.1.5-Containing mRNA Vaccines
Authors: Chalkias, S.; McGhee, N.; Whatley, J. L.; Essink, B.; Brosz, A.; Tomassini, J. E.; Girard, B.; Wu, K.; Edwards, D. K.; Nasir, A.; Lee, D.; Avena, L. E.; Feng, J.; Deng, W.; Montefiori, D. C.; Baden, L. R.; Miller, J. M.; Das, R.
Score: 2048.9, Published: 2023-09-07 DOI: 10.1101/2023.08.22.23293434
Background: Subvariants of the severe acute respiratory syndrome coronavirus (SARS-CoV-2) omicron XBB-lineage have the potential to escape immunity provided by prior infection or vaccination." />
<meta property="og:type" content="article" />
<meta property="og:url" content="https://trxiv.yorks0n.com/posts/infectious-diseases/" /><meta property="article:section" content="posts" />
<meta property="article:published_time" content="2023-09-10T10:36:49+00:00" />
<meta property="article:modified_time" content="2023-09-10T10:36:49+00:00" />

<meta name="twitter:card" content="summary"/>
<meta name="twitter:title" content="infectious diseases"/>
<meta name="twitter:description" content="Safety and Immunogenicity of XBB.1.5-Containing mRNA Vaccines
Authors: Chalkias, S.; McGhee, N.; Whatley, J. L.; Essink, B.; Brosz, A.; Tomassini, J. E.; Girard, B.; Wu, K.; Edwards, D. K.; Nasir, A.; Lee, D.; Avena, L. E.; Feng, J.; Deng, W.; Montefiori, D. C.; Baden, L. R.; Miller, J. M.; Das, R.
Score: 2048.9, Published: 2023-09-07 DOI: 10.1101/2023.08.22.23293434
Background: Subvariants of the severe acute respiratory syndrome coronavirus (SARS-CoV-2) omicron XBB-lineage have the potential to escape immunity provided by prior infection or vaccination."/>


<script type="application/ld+json">
{
  "@context": "https://schema.org",
  "@type": "BreadcrumbList",
  "itemListElement": [, 
    {
      "@type": "ListItem",
      "position":  2 ,
      "name": "Posts",
      "item": "https://trxiv.yorks0n.com/posts/"
    }, 
    {
      "@type": "ListItem",
      "position":  3 ,
      "name": "infectious diseases",
      "item": "https://trxiv.yorks0n.com/posts/infectious-diseases/"
    }
  ]
}
</script>
<script type="application/ld+json">
{
  "@context": "https://schema.org",
  "@type": "BlogPosting",
  "headline": "infectious diseases",
  "name": "infectious diseases",
  "description": "Safety and Immunogenicity of XBB.1.5-Containing mRNA Vaccines\nAuthors: Chalkias, S.; McGhee, N.; Whatley, J. L.; Essink, B.; Brosz, A.; Tomassini, J. E.; Girard, B.; Wu, K.; Edwards, D. K.; Nasir, A.; Lee, D.; Avena, L. E.; Feng, J.; Deng, W.; Montefiori, D. C.; Baden, L. R.; Miller, J. M.; Das, R.\nScore: 2048.9, Published: 2023-09-07 DOI: 10.1101/2023.08.22.23293434\nBackground: Subvariants of the severe acute respiratory syndrome coronavirus (SARS-CoV-2) omicron XBB-lineage have the potential to escape immunity provided by prior infection or vaccination.",
  "keywords": [
    
  ],
  "articleBody": " Safety and Immunogenicity of XBB.1.5-Containing mRNA Vaccines\nAuthors: Chalkias, S.; McGhee, N.; Whatley, J. L.; Essink, B.; Brosz, A.; Tomassini, J. E.; Girard, B.; Wu, K.; Edwards, D. K.; Nasir, A.; Lee, D.; Avena, L. E.; Feng, J.; Deng, W.; Montefiori, D. C.; Baden, L. R.; Miller, J. M.; Das, R.\nScore: 2048.9, Published: 2023-09-07 DOI: 10.1101/2023.08.22.23293434\nBackground: Subvariants of the severe acute respiratory syndrome coronavirus (SARS-CoV-2) omicron XBB-lineage have the potential to escape immunity provided by prior infection or vaccination. For Covid-19 immunizations beginning in the Fall 2023, the U.S. FDA has recommended updating to a monovalent omicron XBB.1.5-containing vaccine. Methods: In this ongoing, phase 2/3 study participants were randomized 1:1 to receive 50-{micro}g doses of mRNA-1273.815 monovalent (50-{micro}g omicron XBB.1.5 spike mRNA) or mRNA-1273.231 bivalent (25-{micro}g omicron XBB.1.5 and 25-{micro}g omicron BA.4/BA.5 spike mRNAs) vaccines, administered as 5th doses, to adults who previously received a primary series and 3rd dose of an original mRNA coronavirus disease 2019 (Covid-19) vaccine, and a 4th dose of a bivalent (omicron BA.4/BA.5 and original SARS-CoV-2) vaccine. Interim safety and immunogenicity data 15 days post-vaccination are presented. Results: In April 2023, participants received mRNA-1273.815 (n=50) and mRNA-1273.231 (n=51). The median intervals from the prior dose of BA.4/BA.5-containing bivalent vaccine were 8.2 and 8.3 months for the mRNA-1273.815 and mRNA-1273.231 groups, respectively. Both vaccines increased neutralizing antibody (nAb) geometric mean titers against all variants tested at day 15 post-booster nAb compared to pre-booster levels. Geometric mean fold-rises from pre-booster titers after the monovalent booster were numerically higher against XBB.1.5, XBB.1.16 and SARS-CoV-2 (D614G) than those of the bivalent booster and were comparable against BA.4/BA.5 and BQ1.1 variants for both vaccines. The monovalent vaccine also elicited nAb responses against omicron XBB.2.3.2, EG.5.1, FL.1.5.1 and BA.2.86 that were similar to those against XBB.1.5 in a subset (n=20) of participants. The occurrence of solicited adverse reactions and unsolicited adverse events were overall similar to those previously reported for the original mRNA-1273 50-{micro}g and omicron BA.4/BA.5-containing bivalent mRNA-1273 vaccines. Conclusion: In this interim analysis, XBB.1.5-containing monovalent and bivalent vaccines elicited potent neutralizing responses against variants of the omicron XBB-lineage (XBB.1.5, XBB.1.6, XBB.2.3.2, EG.5.1, and FL.1.5.1) as well as the recently emerged BA.2.86 variant. The safety profile of the XBB.1.5-containing vaccine was consistent with those of prior vaccines. These results overall indicate that the XBB.1.5-containing mRNA-1273.815 vaccine has the potential to provide protection against these emerging variants and support the Covid-19 vaccine update in 2023-2024 to a monovalent XBB.1.5-containing vaccine.\nEmerging Links Between COVID-19 and Cardiovascular \u0026 Cerebrovascular Thromboembolic Events: A Systematic Review\nAuthors: Agarwal, A.; Panjiyar, B. K.; Patel, D. M.; Ghotra, M.; Husain, M. G. N.; Upadhyay, R. B.\nScore: 277.1, Published: 2023-09-05 DOI: 10.1101/2023.09.05.23295067\nCOVID-19, caused by the SARS-CoV-2 virus, initially identified as a respiratory illness, has increasingly been linked to a broader range of organ complications. This systematic review explores the impact of COVID-19 on cardiovascular and cerebrovascular health, focusing on thromboembolic events in post-COVID patients. A comprehensive literature search was conducted in PubMed and Google Scholar databases up to July 2023, utilizing the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. Studies meeting eligibility criteria were analyzed for outcomes and associations between COVID-19 and cardiovascular and cerebrovascular events. The review includes 6 studies involving over 12 million patients, demonstrating a strong connection between COVID-19 and elevated risks of cardiovascular and cerebrovascular thromboembolic events. The risk of these events is evident in conditions such as ischemic heart disease, stroke, and cardiac arrhythmias. The burden of these events beyond the acute phase of the disease is concerning, warranting further exploration of long-term implications. Variability in event rates among different cohorts and healthcare settings underscores the need for understanding underlying factors influencing these differences. Potential mechanisms behind these events include endothelial dysfunction, systemic inflammation, and viral invasion. Implications for public health policies, clinical guidelines, and future research directions are discussed. This review serves as a valuable resource for healthcare providers, policymakers, and researchers to enhance patient care, outcomes, and preparedness for future waves of COVID-19 infections. However, there remain unexplored aspects of the COVID-19 and thromboembolic events relationship, urging further investigations into mechanistic insights and potential therapeutic interventions.\nQuantity of SARS-CoV-2 RNA copies exhaled per minute during natural breathing over the course of COVID-19 infection\nAuthors: Lane, G.; Zhou, G.; Hultquist, J. F.; Simons, L. M.; Lorenzo-Redondo, R.; Ozer, E. A.; McCarthy, D. M.; Ison, M. G.; Achenbach, C. J.; Wang, X.; Wai, C. M.; Wyatt, E.; Aalsburg, A.; Yang, Q.; Noto, T.; Alisoltani, A.; Ysselstein, D.; Awatramani, R.; Murphy, R.; Theron, G.; Zelano, C.\nScore: 207.4, Published: 2023-09-08 DOI: 10.1101/2023.09.06.23295138\nSARS-CoV-2 is spread through exhaled breath of infected individuals. A fundamental question in understanding transmission of SARS-CoV-2 is how much virus an individual is exhaling into the environment while they breathe, over the course of their infection. Research on viral load dynamics during COVID-19 infection has focused on internal swab specimens, which provide a measure of viral loads inside the respiratory tract, but not on breath. Therefore, the dynamics of viral shedding on exhaled breath over the course of infection are poorly understood. Here, we collected exhaled breath specimens from COVID-19 patients and used RTq-PCR to show that numbers of exhaled SARS-CoV-2 RNA copies during COVID-19 infection do not decrease significantly until day 8 from symptom-onset. COVID-19-positive participants exhaled an average of 80 SARS-CoV-2 viral RNA copies per minute during the first 8 days of infection, with significant variability both between and within individuals, including spikes over 800 copies a minute in some patients. After day 8, there was a steep drop to levels nearing the limit of detection, persisting for up to 20 days. We further found that levels of exhaled viral RNA increased with self-rated symptom-severity, though individual variation was high. Levels of exhaled viral RNA did not differ across age, sex, time of day, vaccination status or viral variant. Our data provide a fine-grained, direct measure of the number of SARS-CoV-2 viral copies exhaled per minute during natural breathing, including 312 breath specimens collected multiple times daily over the course of infection, in order to fill an important gap in our understanding of the time course of exhaled viral loads in COVID-19.\nKinetics and durability of humoral responses to SARS-CoV-2 infection and vaccination\nAuthors: Srivastava, K.; Carreno Quiroz, J. M.; Gleason, C.; Monahan, B.; Singh, G.; Abbad, A.; Tcheou, J.; Raskin, A.; Kleiner, G.; van Bakel, H.; Sordillo, E. M.; PARIS Study Group, ; Krammer, F. M.; Simon, V.\nScore: 447.3, Published: 2023-08-28 DOI: 10.1101/2023.08.26.23294679\nWe analyzed the kinetics and durability of the humoral responses to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and vaccination using \u003e8,000 longitudinal samples collected over a three-year period (April 2020 - April 2023) in the New York City metropolitan area. Upon primary immunization, participants with pre-existing immunity mounted higher antibody responses faster and achieved higher steady-state levels compared to naive individuals. Antibody durability was characterized by two phases: an initial rapid decay, followed by a phase of stabilization with very slow decay resulting in an individual spike binding antibody steady state. Booster vaccination equalized the differences in antibody levels between participants with and without hybrid immunity, but the antibody titers reached decreased with each successive antigen exposure. Break-through infections increased antibody titers to similar levels as an additional vaccine dose in naive individuals. Our study provides strong evidence for the fact that SARS-CoV-2 antibody responses are long lasting, with an initial waning phase followed by a stabilization phase.\nEvolution and neutralization escape of the SARS-CoV-2 BA.2.86 subvariant\nAuthors: Khan, K.; Lustig, G.; Reedoy, K.; Jule, Z.; Romer, C.; Karim, F.; Ganga, Y.; Bernstein, M.; Baig, Z.; Mahlangu, B.; Mnguni, A.; Nzimande, A.; Stock, N.; Kekana, D.; Ntozini, B.; van Deventer, C.; Marshall, T.; Manickchund, N.; Gosnell, B.; Lessells, R.; Abdool Karim, Q.; Abdool Karim, S. S.; Moosa, Y.; de Oliveira, T.; von Gottberg, A.; Wolter, N.; Neher, R. A.; Sigal, A.\nScore: 88.0, Published: 2023-09-08 DOI: 10.1101/2023.09.08.23295250\nOmicron BA.2.86 subvariant differs from Omicron BA.2 as well as recently circulating variants by over 30 mutations in the spike protein alone. Here we report on the first isolation of the live BA.2.86 subvariant from a diagnostic swab collected in South Africa which we tested for escape from neutralizing antibodies and viral replication properties in cell culture. BA.2.86 did not have significantly more escape than Omicron XBB.1.5 from neutralizing immunity elicited by infection of Omicron subvariants ranging from BA.1 to XBB, either by infection alone or as breakthrough infection in vaccinated individuals. Neutralization escape was present relative to earlier strains: BA.2.86 showed extensive escape both relative to ancestral virus in sera from pre-Omicron vaccinated individuals and relative to Omicron BA.1 in sera from Omicron BA.1 infected individuals. We did not observe substantial differences in viral properties in cell culture relative to XBB.1.5. Both BA.2.86 and XBB.1.5 produced infection foci of similar size, had similar cytopathic effect (both lower than ancestral SARS-CoV-2), and had similar replication dynamics. We also investigated the relationship of BA.2.86 to BA.2 sequences and found that the closest were BA.2 samples from Southern Africa circulating in early 2022. These observations suggest that BA.2.86 is more closely related to sequences from Southern Africa than other regions and so may have evolved there, and that evolution led to escape from neutralizing antibodies similar in scale to recently circulating strains of SARS-CoV-2.\nImprovement of immune dysregulation and health-related quality of life in individuals with long COVID at 24-months following SARS-CoV-2 infection\nAuthors: Phetsouphanh, C.; Jacka, B.; Ballouz, S.; Jackson, K. J.; Wilson, D. B.; Manandhar, B.; Klemm, V.; Tan, H.-X.; Wheatley, A.; Aggarwal, A.; Akerman, A.; Milogiannakis, V.; Starr, M.; Cunningham, P.; Turville, S. G.; Kent, S. J.; Byrne, A.; Brew, B. J.; Darley, D. R.; Dore, G. J.; Kelleher, A. D.; Matthews, G. V.\nScore: 97.8, Published: 2023-08-28 DOI: 10.1101/2023.08.27.23294704\nThis study investigated the humoral and cellular immune responses in individuals with long COVID (LC) compared to age and gender matched recovered COVID-19 controls (MC) over 24-months. LC participants showed elevated spike and nucleocapsid IgG levels, higher neutralizing capacity, and increased spike- and nucleocapsid-specific CD4+ T cells, PD-1, and TIM-3 expression on CD4+ and CD8+ T cells at 3- and 8-months, but these differences did not persist at 24-months. Some LC participants had detectable IFN-{gamma} and IFN-{beta}, that was attributed to reinfection and antigen re-exposure. Single-cell RNA sequencing at 24-month timepoint revealed similar immune cell proportions and reconstitution of naive T and B cell subsets in LC. No significant differences in exhaustion scores or antigen-specific T cell clones were observed. These findings suggest resolution of immune activation in LC and return to comparable immune responses between LC and MC over time. Improvement in self-reported health-related quality of life at 24-months was also evident in the majority of LC (62%). PTX3, CRP levels and platelet count were associated with improvements in health-related quality of life.\nHow will COVID-19 persist in the future? Simulating future dynamics of COVID-19 using an agent-based network model\nAuthors: Roubenoff, E.\nScore: 26.4, Published: 2023-09-01 DOI: 10.1101/2023.08.29.23294791\nDespite the United States Center for Disease Control (CDC)s May 2023 expiration of the declared public health emergency pertaining to the COVID-19 pandemic (Silk 2023), approximately 3 years after the first cases of SARS-CoV-2 appeared in the United Sates, thousands of new cases persist daily. Many questions persist about the future dynamics of SARS-CoV-2s in the United States, including: will COVID continue to circulate as a seasonal disease like influenza, and will annual vaccinations be required to prevent outbreaks? In response, we present an Agent Based Networked Simulation of COVID-19 transmission to evaluate recurrent future outbreaks of the disease, accounting for contact heterogeneity and waning vaccine-derived and natural immunity. Our model is parameterized with data collected as part of the Berkeley Interpersonal Contact Survey (BICS; Feehan and Mahmud 2021) and is used to simulate time series of confirmed cases of and deaths due to SARS-CoV-2, paying special attention to seasonal forces and waning immunity (Kronfeld-Schor et al. 2021; X. Liu et al. 2021; Nichols et al. 2021). From the BICS ABM model we simulate SARS-CoV-2 dynamics over the 10-year period beginning in 2021 with waning immunity and inclusion of annual booster doses under a variety of transmission scenarios. We find that SARS-CoV-2 outbreaks are likely to occur frequently, and that distribution of booster doses during certain times of the year--notably in the late winter/early spring--may reduce the severity of a wintertime outbreak depending on the seasonal epidemiology of the pathogen.\nEmergence of neutralizing antibodies associates with clearance of SARS-CoV-2 during HIV-mediated immunosuppression\nAuthors: Karim, F.; Bernstein, M.; Zesuliwe, Z.; Lustig, G.; Upton, J.-L.; Ganga, Y.; Khan, K.; Reedoy, K.; Mazibuko, M.; Govender, K.; Thambu, K.; Ngcobo, N.; Venter, E.; Makhado, Z.; Hanekom, W.; von Gottberg, A.; Abdool Karim, Q.; S. Adbool Karim, S.; Manickchund, N.; Magula, N.; Gosnell, B.; Moore, P. L.; Lessells, R.; de Oliveira, T.; Moosa, Y.; Sigal, A.\nScore: 19.9, Published: 2023-08-21 DOI: 10.1101/2023.08.18.23293746\nTo design effective vaccines and other immune interventions against a pathogen, it is necessary to know which aspect of immunity associates with protection. We investigated whether neutralizing antibodies associate with infection clearance in long-term SARS-CoV-2 infection during HIV-mediated immunosuppression. We monitored neutralizing antibody activity against SARS-CoV-2 over 1 to 2 years in five participants with advanced HIV disease and delayed control of HIV viremia. These participants had persistent SARS-CoV-2 infection ranging from 110 to 289 days which was associated with low or undetectable neutralizing antibody responses. SARS-CoV-2 clearance was associated with the emergence of neutralizing antibodies and occurred in two participants before suppression of HIV viremia, but after some CD4 T cell reconstitution. Vaccination only further increased neutralizing antibody levels in the advanced HIV disease participants who achieved HIV suppression pre-vaccination. During the prolonged SARS-CoV-2 infection we observed widespread evolution which was particularly pronounced in one Delta variant infection. This resulted in high-level escape from Delta-elicited neutralizing antibodies and a virus antigenically distinct from both ancestral SARS-CoV-2 and Omicron XBB in hamster experimental infections. The results offer new evidence that neutralizing antibodies associate with SARS-CoV-2 clearance and argue that successful management of HIV may be necessary to curtail long-term infection and evolution of co-infecting pathogens.\nGenomics-based timely detection of Dengue Virus type I genotypes I and V in Uruguay\nAuthors: Morel, N.; Giovanetti, M.; Fonseca, V.; BurgueNo, A.; Lima, M.; Castro, E.; Guimaraes, N. R.; Iani, F. C. M.; Bormida, V.; Cortinas, M. N.; Ramas, V.; Coppola, L.; Bento, A. I.; Rosewell, A.; Franco, L.; Rico, J. M.; Lourenco, J.; Alcantara, L. C. J.; Chiparelli, H.\nScore: 15.7, Published: 2023-09-06 DOI: 10.1101/2023.09.05.23295075\nWe report the first whole-genome sequences of Dengue Virus type I genotypes I and V from Uruguay, including the first cases ever reported in the country. Through timely genomic analysis, identification of these genotypes was possible, aiding in timely public health responses and intervention strategies to mitigate the impact of dengue outbreaks. Article Summary LineGenomic Analysis for identification of Dengue virus serotype 1 genotypes I and V in Uruguay: an early detection approach\nEnsitrelvir Fumaric Acid in Patients with SARS-CoV-2: A Retrospective Chart Review\nAuthors: Yamato, M.; Kinoshita, M.; Miyazawa, S.; Seki, M.; Mizuno, T.; Sonoyama, T.\nScore: 14.5, Published: 2023-09-03 DOI: 10.1101/2023.09.03.23294865\nIntroductionAntivirals with differing mechanisms of action are needed for COVID-19 treatment; remdesivir is mainly used in hospitalized patients, but additional antivirals are needed in this setting. Ensitrelvir, a 3C-like protease inhibitor, received emergency approval in Japan in November 2022, based on evidence of rapid symptom resolution in non-hospitalized patients, but confirmation of its efficacy in hospitalized patients is lacking. Case presentationsThis case series reports outcomes for all patients who received ensitrelvir whilst hospitalized with SARS-CoV-2 infection at Rinku General Medical Center, Japan (November 2022- April 2023). Thirty-two hospitalized patients received five days of ensitrelvir treatment (375/125 mg). Mean age was 73.5 years and most patients had mild COVID-19. Patients exhibited various underlying diseases, most commonly hypertension (78.1%) and chronic kidney disease (25.0%). Seven (21.9%) patients were on hemodialysis. The most common concomitant medications were antihypertensives (59.4%) and corticosteroids (31.2%); two (6.3%) patients were being treated with rituximab; 27 (84.4%) patients had viral persistence following pre-treatment remdesivir failure. Following ensitrelvir treatment, all patients experienced clinical improvement as assessed by the investigator. No ICU admissions or deaths due to COVID-19 occurred. Viral clearance was recorded in 18 (56.3%) patients by day 5 and 25 (78.1%) patients at final measurement. No new safety signals were observed. DiscussionThis case series represents ensitrelvir clinical efficacy in hospitalized patients with SARS-CoV-2 in a real-world setting. Most patients experienced persistent viral shedding despite pre-treatment with antivirals, and most were considered high-risk due to underlying conditions. Despite this, no patients experienced progression of COVID-19 to severe or critical disease, including those who failed prior remdesivir treatment. The antiviral activity of ensitrelvir demonstrated here indicates it is a viable treatment option for SARS-CoV-2 infection in this setting. ConclusionEnsitrelvir was associated with potent antiviral activity and positive clinical outcomes in high-risk, hospitalized patients with various comorbidities. Trial RegistrationUMIN000051300 Key Summary PointsO_ST_ABSWhy carry out this study?C_ST_ABSO_LIReal-world evidence of ensitrelvir for the treatment of COVID-19, especially in inpatient settings, is required. C_LIO_LIThis was a retrospective cohort analysis, consisting of 32 high-risk hospitalized patients with a range of disease severities and comorbidities, including patients who had experienced remdesivir treatment failure. C_LI What was learned from the study?O_LIAll patients experienced clinical improvement following ensitrelvir treatment, without any worsening COVID-19. C_LIO_LIViral clearance was documented in 78.1% of patients at final viral measurement. C_LIO_LINo new safety signals of ensitrelvir were observed in this analysis. C_LI\n",
  "wordCount" : "2915",
  "inLanguage": "en",
  "datePublished": "2023-09-10T10:36:49Z",
  "dateModified": "2023-09-10T10:36:49Z",
  "mainEntityOfPage": {
    "@type": "WebPage",
    "@id": "https://trxiv.yorks0n.com/posts/infectious-diseases/"
  },
  "publisher": {
    "@type": "Organization",
    "name": "TRxiv2",
    "logo": {
      "@type": "ImageObject",
      "url": "https://trxiv.yorks0n.com/favicon.ico"
    }
  }
}
</script>
</head>

<body class="" id="top">
<script>
    if (localStorage.getItem("pref-theme") === "dark") {
        document.body.classList.add('dark');
    } else if (localStorage.getItem("pref-theme") === "light") {
        document.body.classList.remove('dark')
    } else if (window.matchMedia('(prefers-color-scheme: dark)').matches) {
        document.body.classList.add('dark');
    }

</script>

<header class="header">
    <nav class="nav">
        <div class="logo">
            <a href="https://trxiv.yorks0n.com" accesskey="h" title="TRxiv2 (Alt + H)">TRxiv2</a>
            <div class="logo-switches">
                <button id="theme-toggle" accesskey="t" title="(Alt + T)">
                    <svg id="moon" xmlns="http://www.w3.org/2000/svg" width="24" height="18" viewBox="0 0 24 24"
                        fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round"
                        stroke-linejoin="round">
                        <path d="M21 12.79A9 9 0 1 1 11.21 3 7 7 0 0 0 21 12.79z"></path>
                    </svg>
                    <svg id="sun" xmlns="http://www.w3.org/2000/svg" width="24" height="18" viewBox="0 0 24 24"
                        fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round"
                        stroke-linejoin="round">
                        <circle cx="12" cy="12" r="5"></circle>
                        <line x1="12" y1="1" x2="12" y2="3"></line>
                        <line x1="12" y1="21" x2="12" y2="23"></line>
                        <line x1="4.22" y1="4.22" x2="5.64" y2="5.64"></line>
                        <line x1="18.36" y1="18.36" x2="19.78" y2="19.78"></line>
                        <line x1="1" y1="12" x2="3" y2="12"></line>
                        <line x1="21" y1="12" x2="23" y2="12"></line>
                        <line x1="4.22" y1="19.78" x2="5.64" y2="18.36"></line>
                        <line x1="18.36" y1="5.64" x2="19.78" y2="4.22"></line>
                    </svg>
                </button>
            </div>
        </div>
        <ul id="menu">
        </ul>
    </nav>
</header>
<main class="main">
<article class="post-single">
  <header class="post-header">
    
    <h1 class="post-title">
      infectious diseases
    </h1>
    <div class="post-meta"><span>updated on September 10, 2023</span>

</div>
  </header> 
  <div class="post-content"><div class="accordion accordion-flush" id="accordionFlushExample"><div class="accordion-item">
    <h3 class="accordion-header" id="flush-heading10.1101/2023.08.22.23293434">
      <button class="accordion-button collapsed" type="button" data-bs-toggle="collapse" data-bs-target="#flush-collapse10.1101/2023.08.22.23293434" aria-expanded="false" aria-controls="flush-collapse10.1101/2023.08.22.23293434">
        <p class="paperTitle">Safety and Immunogenicity of XBB.1.5-Containing mRNA Vaccines</p>
      </button>
    </h3>
    <div id="flush-collapse10.1101/2023.08.22.23293434" class="accordion-collapse collapse" aria-labelledby="flush-heading10.1101/2023.08.22.23293434" data-bs-parent="#accordionFlushExample">
      <div class="accordion-body">
        <p class="author">Authors: Chalkias, S.; McGhee, N.; Whatley, J. L.; Essink, B.; Brosz, A.; Tomassini, J. E.; Girard, B.; Wu, K.; Edwards, D. K.; Nasir, A.; Lee, D.; Avena, L. E.; Feng, J.; Deng, W.; Montefiori, D. C.; Baden, L. R.; Miller, J. M.; Das, R.</p>
        <p class="info">Score: 2048.9, Published: 2023-09-07 </p>
        <p class="info">DOI: <a href='https://doi.org/10.1101/2023.08.22.23293434' target='https://doi.org/10.1101/2023.08.22.23293434'> 10.1101/2023.08.22.23293434</a></p>
        <p class="abstract">Background: Subvariants of the severe acute respiratory syndrome coronavirus (SARS-CoV-2) omicron XBB-lineage have the potential to escape immunity provided by prior infection or vaccination. For Covid-19 immunizations beginning in the Fall 2023, the U.S. FDA has recommended updating to a monovalent omicron XBB.1.5-containing vaccine. Methods: In this ongoing, phase 2/3 study participants were randomized 1:1 to receive 50-{micro}g doses of mRNA-1273.815 monovalent (50-{micro}g omicron XBB.1.5 spike mRNA) or mRNA-1273.231 bivalent (25-{micro}g omicron XBB.1.5 and 25-{micro}g omicron BA.4/BA.5 spike mRNAs) vaccines, administered as 5th doses, to adults who previously received a primary series and 3rd dose of an original mRNA coronavirus disease 2019 (Covid-19) vaccine, and a 4th dose of a bivalent (omicron BA.4/BA.5 and original SARS-CoV-2) vaccine. Interim safety and immunogenicity data 15 days post-vaccination are presented. Results: In April 2023, participants received mRNA-1273.815 (n=50) and mRNA-1273.231 (n=51). The median intervals from the prior dose of BA.4/BA.5-containing bivalent vaccine were 8.2 and 8.3 months for the mRNA-1273.815 and mRNA-1273.231 groups, respectively. Both vaccines increased neutralizing antibody (nAb) geometric mean titers against all variants tested at day 15 post-booster nAb compared to pre-booster levels. Geometric mean fold-rises from pre-booster titers after the monovalent booster were numerically higher against XBB.1.5, XBB.1.16 and SARS-CoV-2 (D614G) than those of the bivalent booster and were comparable against BA.4/BA.5 and BQ1.1 variants for both vaccines. The monovalent vaccine also elicited nAb responses against omicron XBB.2.3.2, EG.5.1, FL.1.5.1 and BA.2.86 that were similar to those against XBB.1.5 in a subset (n=20) of participants. The occurrence of solicited adverse reactions and unsolicited adverse events were overall similar to those previously reported for the original mRNA-1273 50-{micro}g and omicron BA.4/BA.5-containing bivalent mRNA-1273 vaccines. Conclusion: In this interim analysis, XBB.1.5-containing monovalent and bivalent vaccines elicited potent neutralizing responses against variants of the omicron XBB-lineage (XBB.1.5, XBB.1.6, XBB.2.3.2, EG.5.1, and FL.1.5.1) as well as the recently emerged BA.2.86 variant. The safety profile of the XBB.1.5-containing vaccine was consistent with those of prior vaccines. These results overall indicate that the XBB.1.5-containing mRNA-1273.815 vaccine has the potential to provide protection against these emerging variants and support the Covid-19 vaccine update in 2023-2024 to a monovalent XBB.1.5-containing vaccine.</p>
      </div>
    </div>
  </div><div class="accordion-item">
    <h3 class="accordion-header" id="flush-heading10.1101/2023.09.05.23295067">
      <button class="accordion-button collapsed" type="button" data-bs-toggle="collapse" data-bs-target="#flush-collapse10.1101/2023.09.05.23295067" aria-expanded="false" aria-controls="flush-collapse10.1101/2023.09.05.23295067">
        <p class="paperTitle">Emerging Links Between COVID-19 and Cardiovascular &amp; Cerebrovascular Thromboembolic Events: A Systematic Review</p>
      </button>
    </h3>
    <div id="flush-collapse10.1101/2023.09.05.23295067" class="accordion-collapse collapse" aria-labelledby="flush-heading10.1101/2023.09.05.23295067" data-bs-parent="#accordionFlushExample">
      <div class="accordion-body">
        <p class="author">Authors: Agarwal, A.; Panjiyar, B. K.; Patel, D. M.; Ghotra, M.; Husain, M. G. N.; Upadhyay, R. B.</p>
        <p class="info">Score: 277.1, Published: 2023-09-05 </p>
        <p class="info">DOI: <a href='https://doi.org/10.1101/2023.09.05.23295067' target='https://doi.org/10.1101/2023.09.05.23295067'> 10.1101/2023.09.05.23295067</a></p>
        <p class="abstract">COVID-19, caused by the SARS-CoV-2 virus, initially identified as a respiratory illness, has increasingly been linked to a broader range of organ complications. This systematic review explores the impact of COVID-19 on cardiovascular and cerebrovascular health, focusing on thromboembolic events in post-COVID patients. A comprehensive literature search was conducted in PubMed and Google Scholar databases up to July 2023, utilizing the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. Studies meeting eligibility criteria were analyzed for outcomes and associations between COVID-19 and cardiovascular and cerebrovascular events. The review includes 6 studies involving over 12 million patients, demonstrating a strong connection between COVID-19 and elevated risks of cardiovascular and cerebrovascular thromboembolic events. The risk of these events is evident in conditions such as ischemic heart disease, stroke, and cardiac arrhythmias. The burden of these events beyond the acute phase of the disease is concerning, warranting further exploration of long-term implications. Variability in event rates among different cohorts and healthcare settings underscores the need for understanding underlying factors influencing these differences. Potential mechanisms behind these events include endothelial dysfunction, systemic inflammation, and viral invasion. Implications for public health policies, clinical guidelines, and future research directions are discussed. This review serves as a valuable resource for healthcare providers, policymakers, and researchers to enhance patient care, outcomes, and preparedness for future waves of COVID-19 infections. However, there remain unexplored aspects of the COVID-19 and thromboembolic events relationship, urging further investigations into mechanistic insights and potential therapeutic interventions.</p>
      </div>
    </div>
  </div><div class="accordion-item">
    <h3 class="accordion-header" id="flush-heading10.1101/2023.09.06.23295138">
      <button class="accordion-button collapsed" type="button" data-bs-toggle="collapse" data-bs-target="#flush-collapse10.1101/2023.09.06.23295138" aria-expanded="false" aria-controls="flush-collapse10.1101/2023.09.06.23295138">
        <p class="paperTitle">Quantity of SARS-CoV-2 RNA copies exhaled per minute during natural breathing over the course of COVID-19 infection</p>
      </button>
    </h3>
    <div id="flush-collapse10.1101/2023.09.06.23295138" class="accordion-collapse collapse" aria-labelledby="flush-heading10.1101/2023.09.06.23295138" data-bs-parent="#accordionFlushExample">
      <div class="accordion-body">
        <p class="author">Authors: Lane, G.; Zhou, G.; Hultquist, J. F.; Simons, L. M.; Lorenzo-Redondo, R.; Ozer, E. A.; McCarthy, D. M.; Ison, M. G.; Achenbach, C. J.; Wang, X.; Wai, C. M.; Wyatt, E.; Aalsburg, A.; Yang, Q.; Noto, T.; Alisoltani, A.; Ysselstein, D.; Awatramani, R.; Murphy, R.; Theron, G.; Zelano, C.</p>
        <p class="info">Score: 207.4, Published: 2023-09-08 </p>
        <p class="info">DOI: <a href='https://doi.org/10.1101/2023.09.06.23295138' target='https://doi.org/10.1101/2023.09.06.23295138'> 10.1101/2023.09.06.23295138</a></p>
        <p class="abstract">SARS-CoV-2 is spread through exhaled breath of infected individuals. A fundamental question in understanding transmission of SARS-CoV-2 is how much virus an individual is exhaling into the environment while they breathe, over the course of their infection. Research on viral load dynamics during COVID-19 infection has focused on internal swab specimens, which provide a measure of viral loads inside the respiratory tract, but not on breath. Therefore, the dynamics of viral shedding on exhaled breath over the course of infection are poorly understood. Here, we collected exhaled breath specimens from COVID-19 patients and used RTq-PCR to show that numbers of exhaled SARS-CoV-2 RNA copies during COVID-19 infection do not decrease significantly until day 8 from symptom-onset. COVID-19-positive participants exhaled an average of 80 SARS-CoV-2 viral RNA copies per minute during the first 8 days of infection, with significant variability both between and within individuals, including spikes over 800 copies a minute in some patients. After day 8, there was a steep drop to levels nearing the limit of detection, persisting for up to 20 days. We further found that levels of exhaled viral RNA increased with self-rated symptom-severity, though individual variation was high. Levels of exhaled viral RNA did not differ across age, sex, time of day, vaccination status or viral variant. Our data provide a fine-grained, direct measure of the number of SARS-CoV-2 viral copies exhaled per minute during natural breathing, including 312 breath specimens collected multiple times daily over the course of infection, in order to fill an important gap in our understanding of the time course of exhaled viral loads in COVID-19.</p>
      </div>
    </div>
  </div><div class="accordion-item">
    <h3 class="accordion-header" id="flush-heading10.1101/2023.08.26.23294679">
      <button class="accordion-button collapsed" type="button" data-bs-toggle="collapse" data-bs-target="#flush-collapse10.1101/2023.08.26.23294679" aria-expanded="false" aria-controls="flush-collapse10.1101/2023.08.26.23294679">
        <p class="paperTitle">Kinetics and durability of humoral responses to SARS-CoV-2 infection and vaccination</p>
      </button>
    </h3>
    <div id="flush-collapse10.1101/2023.08.26.23294679" class="accordion-collapse collapse" aria-labelledby="flush-heading10.1101/2023.08.26.23294679" data-bs-parent="#accordionFlushExample">
      <div class="accordion-body">
        <p class="author">Authors: Srivastava, K.; Carreno Quiroz, J. M.; Gleason, C.; Monahan, B.; Singh, G.; Abbad, A.; Tcheou, J.; Raskin, A.; Kleiner, G.; van Bakel, H.; Sordillo, E. M.; PARIS Study Group,  ; Krammer, F. M.; Simon, V.</p>
        <p class="info">Score: 447.3, Published: 2023-08-28 </p>
        <p class="info">DOI: <a href='https://doi.org/10.1101/2023.08.26.23294679' target='https://doi.org/10.1101/2023.08.26.23294679'> 10.1101/2023.08.26.23294679</a></p>
        <p class="abstract">We analyzed the kinetics and durability of the humoral responses to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and vaccination using &gt;8,000 longitudinal samples collected over a three-year period (April 2020 - April 2023) in the New York City metropolitan area. Upon primary immunization, participants with pre-existing immunity mounted higher antibody responses faster and achieved higher steady-state levels compared to naive individuals. Antibody durability was characterized by two phases: an initial rapid decay, followed by a phase of stabilization with very slow decay resulting in an individual spike binding antibody steady state. Booster vaccination equalized the differences in antibody levels between participants with and without hybrid immunity, but the antibody titers reached decreased with each successive antigen exposure. Break-through infections increased antibody titers to similar levels as an additional vaccine dose in naive individuals. Our study provides strong evidence for the fact that SARS-CoV-2 antibody responses are long lasting, with an initial waning phase followed by a stabilization phase.</p>
      </div>
    </div>
  </div><div class="accordion-item">
    <h3 class="accordion-header" id="flush-heading10.1101/2023.09.08.23295250">
      <button class="accordion-button collapsed" type="button" data-bs-toggle="collapse" data-bs-target="#flush-collapse10.1101/2023.09.08.23295250" aria-expanded="false" aria-controls="flush-collapse10.1101/2023.09.08.23295250">
        <p class="paperTitle">Evolution and neutralization escape of the SARS-CoV-2 BA.2.86 subvariant</p>
      </button>
    </h3>
    <div id="flush-collapse10.1101/2023.09.08.23295250" class="accordion-collapse collapse" aria-labelledby="flush-heading10.1101/2023.09.08.23295250" data-bs-parent="#accordionFlushExample">
      <div class="accordion-body">
        <p class="author">Authors: Khan, K.; Lustig, G.; Reedoy, K.; Jule, Z.; Romer, C.; Karim, F.; Ganga, Y.; Bernstein, M.; Baig, Z.; Mahlangu, B.; Mnguni, A.; Nzimande, A.; Stock, N.; Kekana, D.; Ntozini, B.; van Deventer, C.; Marshall, T.; Manickchund, N.; Gosnell, B.; Lessells, R.; Abdool Karim, Q.; Abdool Karim, S. S.; Moosa, Y.; de Oliveira, T.; von Gottberg, A.; Wolter, N.; Neher, R. A.; Sigal, A.</p>
        <p class="info">Score: 88.0, Published: 2023-09-08 </p>
        <p class="info">DOI: <a href='https://doi.org/10.1101/2023.09.08.23295250' target='https://doi.org/10.1101/2023.09.08.23295250'> 10.1101/2023.09.08.23295250</a></p>
        <p class="abstract">Omicron BA.2.86 subvariant differs from Omicron BA.2 as well as recently circulating variants by over 30 mutations in the spike protein alone. Here we report on the first isolation of the live BA.2.86 subvariant from a diagnostic swab collected in South Africa which we tested for escape from neutralizing antibodies and viral replication properties in cell culture. BA.2.86 did not have significantly more escape than Omicron XBB.1.5 from neutralizing immunity elicited by infection of Omicron subvariants ranging from BA.1 to XBB, either by infection alone or as breakthrough infection in vaccinated individuals. Neutralization escape was present relative to earlier strains: BA.2.86 showed extensive escape both relative to ancestral virus in sera from pre-Omicron vaccinated individuals and relative to Omicron BA.1 in sera from Omicron BA.1 infected individuals. We did not observe substantial differences in viral properties in cell culture relative to XBB.1.5. Both BA.2.86 and XBB.1.5 produced infection foci of similar size, had similar cytopathic effect (both lower than ancestral SARS-CoV-2), and had similar replication dynamics. We also investigated the relationship of BA.2.86 to BA.2 sequences and found that the closest were BA.2 samples from Southern Africa circulating in early 2022. These observations suggest that BA.2.86 is more closely related to sequences from Southern Africa than other regions and so may have evolved there, and that evolution led to escape from neutralizing antibodies similar in scale to recently circulating strains of SARS-CoV-2.</p>
      </div>
    </div>
  </div><div class="accordion-item">
    <h3 class="accordion-header" id="flush-heading10.1101/2023.08.27.23294704">
      <button class="accordion-button collapsed" type="button" data-bs-toggle="collapse" data-bs-target="#flush-collapse10.1101/2023.08.27.23294704" aria-expanded="false" aria-controls="flush-collapse10.1101/2023.08.27.23294704">
        <p class="paperTitle">Improvement of immune dysregulation and health-related quality of life in individuals with long COVID at 24-months following SARS-CoV-2 infection</p>
      </button>
    </h3>
    <div id="flush-collapse10.1101/2023.08.27.23294704" class="accordion-collapse collapse" aria-labelledby="flush-heading10.1101/2023.08.27.23294704" data-bs-parent="#accordionFlushExample">
      <div class="accordion-body">
        <p class="author">Authors: Phetsouphanh, C.; Jacka, B.; Ballouz, S.; Jackson, K. J.; Wilson, D. B.; Manandhar, B.; Klemm, V.; Tan, H.-X.; Wheatley, A.; Aggarwal, A.; Akerman, A.; Milogiannakis, V.; Starr, M.; Cunningham, P.; Turville, S. G.; Kent, S. J.; Byrne, A.; Brew, B. J.; Darley, D. R.; Dore, G. J.; Kelleher, A. D.; Matthews, G. V.</p>
        <p class="info">Score: 97.8, Published: 2023-08-28 </p>
        <p class="info">DOI: <a href='https://doi.org/10.1101/2023.08.27.23294704' target='https://doi.org/10.1101/2023.08.27.23294704'> 10.1101/2023.08.27.23294704</a></p>
        <p class="abstract">This study investigated the humoral and cellular immune responses in individuals with long COVID (LC) compared to age and gender matched recovered COVID-19 controls (MC) over 24-months. LC participants showed elevated spike and nucleocapsid IgG levels, higher neutralizing capacity, and increased spike- and nucleocapsid-specific CD4&#43; T cells, PD-1, and TIM-3 expression on CD4&#43; and CD8&#43; T cells at 3- and 8-months, but these differences did not persist at 24-months. Some LC participants had detectable IFN-{gamma} and IFN-{beta}, that was attributed to reinfection and antigen re-exposure. Single-cell RNA sequencing at 24-month timepoint revealed similar immune cell proportions and reconstitution of naive T and B cell subsets in LC. No significant differences in exhaustion scores or antigen-specific T cell clones were observed. These findings suggest resolution of immune activation in LC and return to comparable immune responses between LC and MC over time. Improvement in self-reported health-related quality of life at 24-months was also evident in the majority of LC (62%). PTX3, CRP levels and platelet count were associated with improvements in health-related quality of life.</p>
      </div>
    </div>
  </div><div class="accordion-item">
    <h3 class="accordion-header" id="flush-heading10.1101/2023.08.29.23294791">
      <button class="accordion-button collapsed" type="button" data-bs-toggle="collapse" data-bs-target="#flush-collapse10.1101/2023.08.29.23294791" aria-expanded="false" aria-controls="flush-collapse10.1101/2023.08.29.23294791">
        <p class="paperTitle">How will COVID-19 persist in the future? Simulating future dynamics of COVID-19 using an agent-based network model</p>
      </button>
    </h3>
    <div id="flush-collapse10.1101/2023.08.29.23294791" class="accordion-collapse collapse" aria-labelledby="flush-heading10.1101/2023.08.29.23294791" data-bs-parent="#accordionFlushExample">
      <div class="accordion-body">
        <p class="author">Authors: Roubenoff, E.</p>
        <p class="info">Score: 26.4, Published: 2023-09-01 </p>
        <p class="info">DOI: <a href='https://doi.org/10.1101/2023.08.29.23294791' target='https://doi.org/10.1101/2023.08.29.23294791'> 10.1101/2023.08.29.23294791</a></p>
        <p class="abstract">Despite the United States Center for Disease Control (CDC)s May 2023 expiration of the declared public health emergency pertaining to the COVID-19 pandemic (Silk 2023), approximately 3 years after the first cases of SARS-CoV-2 appeared in the United Sates, thousands of new cases persist daily. Many questions persist about the future dynamics of SARS-CoV-2s in the United States, including: will COVID continue to circulate as a seasonal disease like influenza, and will annual vaccinations be required to prevent outbreaks? In response, we present an Agent Based Networked Simulation of COVID-19 transmission to evaluate recurrent future outbreaks of the disease, accounting for contact heterogeneity and waning vaccine-derived and natural immunity. Our model is parameterized with data collected as part of the Berkeley Interpersonal Contact Survey (BICS; Feehan and Mahmud 2021) and is used to simulate time series of confirmed cases of and deaths due to SARS-CoV-2, paying special attention to seasonal forces and waning immunity (Kronfeld-Schor et al. 2021; X. Liu et al. 2021; Nichols et al. 2021). From the BICS ABM model we simulate SARS-CoV-2 dynamics over the 10-year period beginning in 2021 with waning immunity and inclusion of annual booster doses under a variety of transmission scenarios. We find that SARS-CoV-2 outbreaks are likely to occur frequently, and that distribution of booster doses during certain times of the year--notably in the late winter/early spring--may reduce the severity of a wintertime outbreak depending on the seasonal epidemiology of the pathogen.</p>
      </div>
    </div>
  </div><div class="accordion-item">
    <h3 class="accordion-header" id="flush-heading10.1101/2023.08.18.23293746">
      <button class="accordion-button collapsed" type="button" data-bs-toggle="collapse" data-bs-target="#flush-collapse10.1101/2023.08.18.23293746" aria-expanded="false" aria-controls="flush-collapse10.1101/2023.08.18.23293746">
        <p class="paperTitle">Emergence of neutralizing antibodies associates with clearance of SARS-CoV-2 during HIV-mediated immunosuppression</p>
      </button>
    </h3>
    <div id="flush-collapse10.1101/2023.08.18.23293746" class="accordion-collapse collapse" aria-labelledby="flush-heading10.1101/2023.08.18.23293746" data-bs-parent="#accordionFlushExample">
      <div class="accordion-body">
        <p class="author">Authors: Karim, F.; Bernstein, M.; Zesuliwe, Z.; Lustig, G.; Upton, J.-L.; Ganga, Y.; Khan, K.; Reedoy, K.; Mazibuko, M.; Govender, K.; Thambu, K.; Ngcobo, N.; Venter, E.; Makhado, Z.; Hanekom, W.; von Gottberg, A.; Abdool Karim, Q.; S. Adbool Karim, S.; Manickchund, N.; Magula, N.; Gosnell, B.; Moore, P. L.; Lessells, R.; de Oliveira, T.; Moosa, Y.; Sigal, A.</p>
        <p class="info">Score: 19.9, Published: 2023-08-21 </p>
        <p class="info">DOI: <a href='https://doi.org/10.1101/2023.08.18.23293746' target='https://doi.org/10.1101/2023.08.18.23293746'> 10.1101/2023.08.18.23293746</a></p>
        <p class="abstract">To design effective vaccines and other immune interventions against a pathogen, it is necessary to know which aspect of immunity associates with protection. We investigated whether neutralizing antibodies associate with infection clearance in long-term SARS-CoV-2 infection during HIV-mediated immunosuppression. We monitored neutralizing antibody activity against SARS-CoV-2 over 1 to 2 years in five participants with advanced HIV disease and delayed control of HIV viremia. These participants had persistent SARS-CoV-2 infection ranging from 110 to 289 days which was associated with low or undetectable neutralizing antibody responses. SARS-CoV-2 clearance was associated with the emergence of neutralizing antibodies and occurred in two participants before suppression of HIV viremia, but after some CD4 T cell reconstitution. Vaccination only further increased neutralizing antibody levels in the advanced HIV disease participants who achieved HIV suppression pre-vaccination. During the prolonged SARS-CoV-2 infection we observed widespread evolution which was particularly pronounced in one Delta variant infection. This resulted in high-level escape from Delta-elicited neutralizing antibodies and a virus antigenically distinct from both ancestral SARS-CoV-2 and Omicron XBB in hamster experimental infections. The results offer new evidence that neutralizing antibodies associate with SARS-CoV-2 clearance and argue that successful management of HIV may be necessary to curtail long-term infection and evolution of co-infecting pathogens.</p>
      </div>
    </div>
  </div><div class="accordion-item">
    <h3 class="accordion-header" id="flush-heading10.1101/2023.09.05.23295075">
      <button class="accordion-button collapsed" type="button" data-bs-toggle="collapse" data-bs-target="#flush-collapse10.1101/2023.09.05.23295075" aria-expanded="false" aria-controls="flush-collapse10.1101/2023.09.05.23295075">
        <p class="paperTitle">Genomics-based timely detection of Dengue Virus type I genotypes I and V in Uruguay</p>
      </button>
    </h3>
    <div id="flush-collapse10.1101/2023.09.05.23295075" class="accordion-collapse collapse" aria-labelledby="flush-heading10.1101/2023.09.05.23295075" data-bs-parent="#accordionFlushExample">
      <div class="accordion-body">
        <p class="author">Authors: Morel, N.; Giovanetti, M.; Fonseca, V.; BurgueNo, A.; Lima, M.; Castro, E.; Guimaraes, N. R.; Iani, F. C. M.; Bormida, V.; Cortinas, M. N.; Ramas, V.; Coppola, L.; Bento, A. I.; Rosewell, A.; Franco, L.; Rico, J. M.; Lourenco, J.; Alcantara, L. C. J.; Chiparelli, H.</p>
        <p class="info">Score: 15.7, Published: 2023-09-06 </p>
        <p class="info">DOI: <a href='https://doi.org/10.1101/2023.09.05.23295075' target='https://doi.org/10.1101/2023.09.05.23295075'> 10.1101/2023.09.05.23295075</a></p>
        <p class="abstract">We report the first whole-genome sequences of Dengue Virus type I genotypes I and V from Uruguay, including the first cases ever reported in the country. Through timely genomic analysis, identification of these genotypes was possible, aiding in timely public health responses and intervention strategies to mitigate the impact of dengue outbreaks.

Article Summary LineGenomic Analysis for identification of Dengue virus serotype 1 genotypes I and V in Uruguay: an early detection approach</p>
      </div>
    </div>
  </div><div class="accordion-item">
    <h3 class="accordion-header" id="flush-heading10.1101/2023.09.03.23294865">
      <button class="accordion-button collapsed" type="button" data-bs-toggle="collapse" data-bs-target="#flush-collapse10.1101/2023.09.03.23294865" aria-expanded="false" aria-controls="flush-collapse10.1101/2023.09.03.23294865">
        <p class="paperTitle">Ensitrelvir Fumaric Acid in Patients with SARS-CoV-2: A Retrospective Chart Review</p>
      </button>
    </h3>
    <div id="flush-collapse10.1101/2023.09.03.23294865" class="accordion-collapse collapse" aria-labelledby="flush-heading10.1101/2023.09.03.23294865" data-bs-parent="#accordionFlushExample">
      <div class="accordion-body">
        <p class="author">Authors: Yamato, M.; Kinoshita, M.; Miyazawa, S.; Seki, M.; Mizuno, T.; Sonoyama, T.</p>
        <p class="info">Score: 14.5, Published: 2023-09-03 </p>
        <p class="info">DOI: <a href='https://doi.org/10.1101/2023.09.03.23294865' target='https://doi.org/10.1101/2023.09.03.23294865'> 10.1101/2023.09.03.23294865</a></p>
        <p class="abstract">IntroductionAntivirals with differing mechanisms of action are needed for COVID-19 treatment; remdesivir is mainly used in hospitalized patients, but additional antivirals are needed in this setting. Ensitrelvir, a 3C-like protease inhibitor, received emergency approval in Japan in November 2022, based on evidence of rapid symptom resolution in non-hospitalized patients, but confirmation of its efficacy in hospitalized patients is lacking.

Case presentationsThis case series reports outcomes for all patients who received ensitrelvir whilst hospitalized with SARS-CoV-2 infection at Rinku General Medical Center, Japan (November 2022- April 2023). Thirty-two hospitalized patients received five days of ensitrelvir treatment (375/125 mg). Mean age was 73.5 years and most patients had mild COVID-19. Patients exhibited various underlying diseases, most commonly hypertension (78.1%) and chronic kidney disease (25.0%). Seven (21.9%) patients were on hemodialysis. The most common concomitant medications were antihypertensives (59.4%) and corticosteroids (31.2%); two (6.3%) patients were being treated with rituximab; 27 (84.4%) patients had viral persistence following pre-treatment remdesivir failure. Following ensitrelvir treatment, all patients experienced clinical improvement as assessed by the investigator. No ICU admissions or deaths due to COVID-19 occurred. Viral clearance was recorded in 18 (56.3%) patients by day 5 and 25 (78.1%) patients at final measurement. No new safety signals were observed.

DiscussionThis case series represents ensitrelvir clinical efficacy in hospitalized patients with SARS-CoV-2 in a real-world setting. Most patients experienced persistent viral shedding despite pre-treatment with antivirals, and most were considered high-risk due to underlying conditions. Despite this, no patients experienced progression of COVID-19 to severe or critical disease, including those who failed prior remdesivir treatment. The antiviral activity of ensitrelvir demonstrated here indicates it is a viable treatment option for SARS-CoV-2 infection in this setting.

ConclusionEnsitrelvir was associated with potent antiviral activity and positive clinical outcomes in high-risk, hospitalized patients with various comorbidities.

Trial RegistrationUMIN000051300

Key Summary PointsO_ST_ABSWhy carry out this study?C_ST_ABSO_LIReal-world evidence of ensitrelvir for the treatment of COVID-19, especially in inpatient settings, is required.
C_LIO_LIThis was a retrospective cohort analysis, consisting of 32 high-risk hospitalized patients with a range of disease severities and comorbidities, including patients who had experienced remdesivir treatment failure.
C_LI

What was learned from the study?O_LIAll patients experienced clinical improvement following ensitrelvir treatment, without any worsening COVID-19.
C_LIO_LIViral clearance was documented in 78.1% of patients at final viral measurement.
C_LIO_LINo new safety signals of ensitrelvir were observed in this analysis.
C_LI</p>
      </div>
    </div>
  </div>
</div>









<script src="/js/bundle.min.js" defer></script>



  </div>

  <footer class="post-footer">
    <ul class="post-tags">
    </ul>
  </footer>
</article>
    </main>
    
<footer class="footer">
    <span>&copy; 2023 <a href="https://trxiv.yorks0n.com">TRxiv2</a></span>
    <span>
         Made by Yorkson
    </span>
</footer>
<a href="#top" aria-label="go to top" title="Go to Top (Alt + G)" class="top-link" id="top-link" accesskey="g">
    <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 12 6" fill="currentColor">
        <path d="M12 6H0l6-6z" />
    </svg>
</a>

<script>
    let menu = document.getElementById('menu')
    if (menu) {
        menu.scrollLeft = localStorage.getItem("menu-scroll-position");
        menu.onscroll = function () {
            localStorage.setItem("menu-scroll-position", menu.scrollLeft);
        }
    }

    document.querySelectorAll('a[href^="#"]').forEach(anchor => {
        anchor.addEventListener("click", function (e) {
            e.preventDefault();
            var id = this.getAttribute("href").substr(1);
            if (!window.matchMedia('(prefers-reduced-motion: reduce)').matches) {
                document.querySelector(`[id='${decodeURIComponent(id)}']`).scrollIntoView({
                    behavior: "smooth"
                });
            } else {
                document.querySelector(`[id='${decodeURIComponent(id)}']`).scrollIntoView();
            }
            if (id === "top") {
                history.replaceState(null, null, " ");
            } else {
                history.pushState(null, null, `#${id}`);
            }
        });
    });

</script>
<script>
    var mybutton = document.getElementById("top-link");
    window.onscroll = function () {
        if (document.body.scrollTop > 800 || document.documentElement.scrollTop > 800) {
            mybutton.style.visibility = "visible";
            mybutton.style.opacity = "1";
        } else {
            mybutton.style.visibility = "hidden";
            mybutton.style.opacity = "0";
        }
    };

</script>
<script>
    document.getElementById("theme-toggle").addEventListener("click", () => {
        if (document.body.className.includes("dark")) {
            document.body.classList.remove('dark');
            localStorage.setItem("pref-theme", 'light');
        } else {
            document.body.classList.add('dark');
            localStorage.setItem("pref-theme", 'dark');
        }
    })

</script>
</body>

</html>
